--- title: "FDA clears Zyn to be marketed as less harmful than cigarettes" description: "The U.S. Food and Drug Administration has authorized Philip Morris International to market its Zyn nicotine pouches with a claim that switching from cigarettes lowers the risk of serious disease — a first for nicotine pouches that has divided public-health experts." category: "Business" category_url: https://newsparlor.com/category/business author: "James Whitmore" published: 2026-06-30T18:14:00.000Z updated: 2026-06-30T18:14:00.000Z canonical: https://newsparlor.com/article/fda-zyn-nicotine-pouches-reduced-risk tags: ["fda", "zyn", "nicotine", "tobacco", "public-health"] --- # FDA clears Zyn to be marketed as less harmful than cigarettes The U.S. Food and Drug Administration has authorized Philip Morris International to market its Zyn nicotine pouches with a claim that switching from cigarettes lowers the risk of serious disease — a first for nicotine pouches that has divided public-health experts. The Food and Drug Administration has taken a notable step in tobacco regulation, allowing the maker of Zyn to tell smokers that its nicotine pouches are a less harmful alternative to cigarettes. ## What the FDA authorized In an order issued June 30, the agency authorized Philip Morris International to market Zyn with the claim that "using Zyn instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis," [CNBC reported](https://www.cnbc.com/2026/06/30/fda-zyn-philip-morris-nicotine-pouches-cigarettes-trump.html). The decision, made through the FDA's "modified risk tobacco product" pathway, is the first of its kind for nicotine pouches — small pouches placed between the lip and gum that deliver nicotine without tobacco smoke or leaf. ## The FDA's reasoning The agency concluded that the pouches contain far lower levels of the harmful chemicals found in cigarette smoke, and that the evidence showed adult smokers who switch completely to Zyn could reduce their risk of tobacco-related disease — a benefit, it judged, to public health overall. The order follows the FDA's January 2025 decision authorizing Zyn for sale in the first place. ## 'Less harmful' is not 'safe' The FDA was careful to qualify the move. The authorization does not mean the products are safe or "FDA approved," the agency stressed: the pouches still deliver addictive nicotine and carry health risks, and the reduced-risk claim applies only to smokers who switch entirely — not to people who do not use tobacco, and especially not to young people. ## A fast-growing product Zyn has become one of the fastest-growing nicotine products in the United States. Philip Morris, which acquired the brand through its 2022 purchase of Swedish Match, reported selling around 794 million cans in 2025 — more than double its 2023 volume — and the pouches dominate the U.S. nicotine-pouch market. ## A divided response Harm-reduction advocates welcomed the decision. Groups such as the [R Street Institute](https://www.rstreet.org/outreach/r-street-comments-on-the-mrtpa-for-zyn-nicotine-products/) argue that clear, evidence-based labeling can help move some of the country's tens of millions of adult smokers off far more dangerous cigarettes, potentially saving lives. Public-health critics counter that the bigger danger is youth uptake. Use of nicotine pouches among American teenagers [rose in 2024](https://www.forbes.com/sites/joshuacohen/2025/07/04/rise-in-teenage-use-of-nicotine-pouches-in-us-has-some-experts-alarmed/), and groups including the American Heart Association warn that nicotine raises blood pressure and heart rate and can harm the still-developing brains of adolescents. They worry that discreet, flavored pouches appeal to minors despite age restrictions. The FDA said it would monitor youth use closely and retains the power to withdraw the authorization if it surges — leaving the decision's ultimate verdict to rest on whether Zyn moves adults away from cigarettes without drawing a new generation into nicotine.